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Abstract
Background: Breast cancer is the most frequent cause of cancer death in women worldwide, but global disparities
in breast cancer control persist, due to a lack of a comprehensive breast cancer control strategy in many countries.
Objectives: To identify and compare the need for breast cancer control strategies in Asia, Latin America and the
Middle East/North Africa and to develop a common framework to guide the development of national breast
cancer control strategies.
Methods: Data were derived from open-ended, semi-structured interviews conducted in 2007 with 221 clinicians,
policy makers, and patient advocates; stratified across Asia (n = 97), Latin America (n = 46), the Middle East/North
Africa (ME/NA) (n = 39) and Australia and Canada (n = 39). Respondents were identified using purposive and
snowballing sampling. Interpretation of the data utilized interpretive phenomenological analysis where transcripts
and field notes were coded and analyzed and common themes were identified. Analysis of regional variation was
conducted based on the frequency of discussion and the writing of the manuscript followed the RATS guidelines.
Results: Analysis revealed four major themes that form the foundation for developing national breast cancer
control strategies: 1) building capacity; 2) developing evidence; 3) removing barriers; and 4) promoting advocacy -
each specified across five sub-ordinate dimensions. The propensity to discuss most dimensions was similar across
regions, but managing advocacy was discussed more frequently (p = 0.004) and organized advocacy was discussed
less frequently (p < 0.001) in Australia and Canada.
Conclusions: This unique research identified common themes for the development of breast cancer control
strategies, grounded in the experience of local practitioners, policy makers and advocacy leaders across diverse
regions. Future research should be aimed at gathering a wider array of experiences, including those of patients.
Background
Breast cancer ranks as the fifth cause of death from can-
cer overall, but it is still the most frequent cause of can-
cer death in women in both developing and developed
regions [1]. As such, breast cancer control has become a
global imperative, yet global inequities persist [2,3].
Many lesser developed countries in Asia, Latin America,
the Middle East and North Africa lack adequate breast
cancer services for screening and treatment and
experience higher mortality rates compared to more
favorable survival from breast cancer in (high-incidence)
developed regions [4-6]. This gap will widen further as
many recent advances in early detection and treatment
remain largely confined to industrialized nations [7] and
significant disparities in breast cancer research exist [8].
To address disparities in breast cancer control, a con-
certed international effort is necessary [9]. Such an
effort must be supported and informed by evidence on
national priorities for breast cancer control.
The purpose of this study was to identify and compare
important breast cancer control strategies in Asia, Latin
America and the Middle East/North Africa to develop a
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national breast cancer control strategies. This is an
important research question, as little can be found in
the literature on the perceived public policy needs of
smaller or lower-resourced countries. While several
international organizations have documented cancer
control strategies or therapeutic guidelines [10,11], this
study identified elements of breast cancer control strat-
egy relevant to public policy and clinical practice in the
study countries. This was achieved through the use of
qualitative research methods to identify strategies rele-
vant to a variety of stakeholders (clinicians, policy
makers and patient advocates). The regions covered in
this study (Asia, Latin America, and the Middle East/
North Africa) account for approximately 60% of the
world’s population of women and a growing percentage
of the incident cases of breast cancer [12]. Australia and
Canada were included in the study as controls. Data
from these countries helped identify some factors that
may have been somewhat neglected in the other coun-
tries. Departing from traditional qualitative methods, we
interviewed a large number of respondents to facilitate a
comparison of the similarities and differences between
regions and our controls.
This unique study is the first to highlight the special
challenges smaller, lower-resourced countries face to
achieve breast cancer control. Our research can be used
to inform such countries on the development of breast
cancer control strategies that are broader than the crea-
tion of clinical guidelines. We also demonstrate the
value of qualitative methods in informing public policy.
Methods
We utilized qualitative research to identify breast cancer
needs from the perspective of various stakeholders
[13-15], a method well suited to exploratory studies
aimed at understanding the needs and experiences of
the respondents [16,17]. We utilized a very large num-
ber of interviews to gather data on a diverse range of
experiences and to facilitate a simple statistical compari-
son of the propensity to discuss themes by region.
Countries were selected by a group of advisors repre-
senting breast cancer experts from across each region
with a goal of at least 200 qualified respondents repre-
senting medicine, as well as policy and patient advocacy
where they existed. Respondents were identified through
a combination of purposive and snowball sampling
methods [16,18] to ensure that we identified a breadth
and depth of experience and knowledge in breast cancer
clinical practice, policy making, and patient advocacy
from across these diverse regions, based on explicit
inclusion criteria (Table 1).
Target respondents were initially identified from a lit-
erature review, engagement with content experts and via
other respondents. All were sent an invitation letter out-
lining the purpose of the study, the funding source and
the potential benefits and risks (which were minimal) of
the study. As seen in Table 2 of 375 identified target
respondents, 75 did not respond, often due to invalid
contact details.
All potential respondents were contacted by tele-
phone, and questions were asked to confirm eligibility
and to schedule a subsequent complete interview in per-
son or by telephone. A follow-up letter or email was
sent within two weeks if no reply was received, with a
translation for those target respondents for whom Eng-
lish was not a primary language. If no reply was received
within two weeks, or if the email address or letter was
not deliverable, the study team attempted calling them
by telephone to verify their interest in participation.
Upon verification of interest and eligibility, the interview
was scheduled and conducted. From initial contact, 53
were not eligible because they did not meet inclusion
criteria. A further 18 refused to participate, most often
citing a lack of time, although one respondent refused
to participate without financial compensation, and four
due to industry funding of the study.
The final 221 interviews were conducted and coded by
a team of 10 experienced and culturally competent field
workers led by a study co-author (BB) who conducted
over a quarter of the interviews. No field worker was
directly involved in breast cancer nor previously advo-
cated for breast cancer control. Hence, the research
took little in the way of bias into the interviews, allow-
ing for a very neutral documentation of the study find-
ings. This said, we acknowledge several possible sources
of bias related to the study team. First, countries
engaged in internal or external conflict were excluded to
ensure the safety of the research team. Second, central
and eastern Europe were excluded as another organiza-
tion was actively recruiting similar study subjects for a
study on clinical breast cancer guidelines [9] and the
study team did not want the two studies to be confused.
Finally, given that English was the common language of
the interviewers, they may have inadvertently biased the
interpretation and analysis of responses towards Wes-
tern concepts. The focus on English may also have led
to a biased sample as verification of eligibility often
relied upon publication in peer reviewed journals and
review of conference proceedings, both of which are
biased towards English-language publications. The inter-
pretation of the study results, and the subsequent identi-
fication of the taxonomy of key themes, was developed
by the lead author (JB) in conjunction with other inves-
tigators on the study. This coding was done with all
identifiers removed, with the exception of region, which
facilitated an equal weighting of the data from all
respondents. In addition, an external panel of non-
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lysis, results and conclusions.
Prior to the start of each interview, respondents were
again informed about the purpose of the study, the
source of the study funding, the risks and benefits of
participating and that, while the results of the study may
be shared in the public domain and respondents may be
quoted verbatim, the content of the interview would be
kept anonymous and confidential. Given the nature of
the study, the minimal risks involved, and the anon-
ymous nature of the study data, the study was exempt
from any formal ethics review.
Interviews were conducted using a standardized inter-
view protocol that had been extensively piloted. Inter-
views began with a ‘grand tour’ question: “What are the
most significant medical or other challenges that you see
yourself facing in the next few years with regards to
breast cancer?” Specific probes were used to gain more
Table 1 Inclusion criteria
Respondents Definition
Medical thought
leader
Initial list identification:
￿ Individuals involved in breast cancer medicine with a history of significant publications and presentations at major
medical and scientific symposia
￿ Heads of leading local medical schools and/or research-based teaching hospitals or cancer centers
￿ Leaders of local societies relevant to breast cancer medicine or members of national cancer study groups, breast cancer
research councils, or tumor boards
￿ Individuals with an active and wide publication history or those who had made presentations within the past few years
at the American Society of Clinical Oncology (ASCO), St. Gallen, and the San Antonio Breast Cancer Symposium (SABCS)
The list was then cross-checked to assess if these clinicians were:
￿ Heads of local leading medical schools and/or research-based teaching hospitals or cancer centers; and/or
￿ Leaders of breast cancer medical or other relevant medical societies responsible for breast cancer medicine; and/or
￿ Members of national cancer study groups, breast cancer research councils, and/or national tumor boards.
Policy maker The selection of policy thought leaders was based on:
￿ Information obtained from the Ministries of Health which recommended the appropriate personnel in charge of breast
cancer policy, funding, screening, and public education
￿ In most cases, nomination and/or validation by the medical thought leaders and/or advocacy leaders.
Patient advocacy
leader
Advocacy leader selection came from:
￿ Referrals by medical or public policy thought leaders; and/or
￿ Independent internet searches and media citations; and/or
￿ Other advocacy leaders both domestically and internationally.
Table 2 Respondents and non-respondents by region
Asia Latin America Middle East/North Africa Australia and Canada Total
Targets (total) 127 83 67 90 375
Excluded from analysis
No response 14 21 12 28 75
Refused 4 4 3 7 18
Not eligible 15 12 10 16 53
Included in analysis
Physician 27 26 19 10 82
Surgeon 16 3 0 0 19
Hospital manager 22 12 10 6 50
Academic 11 4 6 5 26
Researcher 11 0 3 5 19
Nurse 0 0 0 3 3
Policy maker 4 1 1 4 10
Patient advocate 3 0 3 6 12
All 94 46 42 39 221
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opportunities and involvement of other stakeholders.
Interviews lasting 1 to 1.5 hours were conducted in per-
son or by telephone in English or in the respondent’s
native language by trained fieldworkers with extensive
experience conducting medical/scientific interviews in
the relevant countries. When conducted in the intervie-
wee’s native language, the field notes were immediately
translated by the interviewer fluent in both languages.
Data were analyzed both qualitatively and semi-quan-
titatively to aid both identification and comparison of
themes respectively. The identification of themes uti-
lized Interpretive Phenomenological Analysis in order to
capture respondents’ direct experience with breast can-
cer control in their own countries [19]. Analysis was
facilitated through the construction of a standardized
coding protocol that was iteratively developed by the
research team.
Coded transcripts and field notes were then compared,
and a taxonomy consisting of themes and dimensions
was developed without reference to any pre-existing
conceptualization of breast cancer control strategies.
Consistent with the method of analysis [19], representa-
tive quotes were extracted to illustrate the key themes.
We did not attribute the quotes to any region or
respondent for two important reasons. First, as part of
the consent process, respondents were informed that
they would not be linked to their responses. Second,
quotes were identified for their generality, and hence if
we attributed the quotes even to regions readers would
be compelled to find qualitative differences, rather the
commonalities in the factors identified. This said, we
subsequently used a more robust statistical approach to
explore variations in the propensity to discuss the
themes that we identified.
We also used semi-quantitative analysis to compare
responses across regions. Here we estimated the propen-
sity, calculated as a percentage of respondents, for dis-
cussion of each of the final coded themes by region
[20]. We did not account for multiple references to a
theme within an interview with a single respondent (i.e.
we map the propensity of referring to each item at least
once within an interview). To test for differences in
these propensities of discussion of the 20 dimensions
(measured as a percentage of respondents in each region
who discussed the dimension) ANOVA was used, with
the null hypotheses that the percentage of respondents
discussing any particular dimension was identical. In
cases where the ANOVA identified a significant differ-
ence across the regions (p < 0.05) for a particular
dimension, we subsequently conducted a multiple pair-
wise comparisons test using the Mariscuillo procedure
[21,22] to further compare differences across the four
regions for that dimension. Based on this test, we
identified which of the four regions were statistically dif-
ferent from each other region in terms of the percentage
of respondents referring to the dimension.
Several techniques were used to ensure that data ana-
lysis was systematic and verifiable, as recommended for
qualitative research [18,19]. Triangulation methods were
used in the early development of the study protocol,
during the pilot phase, during the development of the
coding system and for interpretation of the data. During
the field work, data were prospectively coded using an
evolving coding manual. The taxonomy was developed
by consensus, informed by qualitative and quantitative
analysis of the data. Early results were presented at sev-
eral workshops at a number of international breast can-
cer meetings, with many of the study respondents and
other world leaders in breast cancer participating. Dur-
ing these meetings, early stage results were commented
upon, with many of the participants contributing to the
interpretation of the data. Finally, we utilized the RATS
guidelines to ensure all relevant information was
included in the manuscript [23,24].
Results
As previously seen in Table 2 the final sample of
respondents included a broad range of stakeholders with
relevant experiences and understanding of breast cancer
control, including physicians, surgeons, hospital man-
agers, academics, researchers, nurses, policy makers, and
patient advocates. The total number of respondents was
221 spanning 29 countries (see Figure 1).
Taxonomy of results
Based on the analysis of the interview data, national
breast cancer control strategies can be described across
four broad themes: building capacity, developing evi-
dence, removing barriers, and promoting advocacy. Table
3 summarizes these themes and the five dimensions
contained in each theme.
Theme 1: Building Capacity
The theme of building capacity represents dimensions
such as developing the capacity for science and research,
the need for skilled nurses, funding and development of
research infrastructure, collecting and disseminating
national statistics,a n dpublic education of the issues
associated with breast cancer. Representative quotes for
the theme of building capacity are presented in Table 4.
Capacity for science and research was commonly
addressed in terms of insufficient funding of clinical
science and a lack of trained human resources to sup-
port basic science and clinical research. As one respon-
dent stated, the responsibility may fall on the individual
investigator to “...educate nurses and other staff to do
research, because the government will not do this or fund
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mass of local basic and clinical research and identified
roles for both national governments and the interna-
tional community to support research activity.
Skilled nurses were cited in each region in terms of
the need for more trained nurses to support breast can-
cer patient care, education, and research, as well as the
need to be able to retain such staff. As one respondent
put it, currently skilled nurses are “...outnumbered in
terms of patients. In oncology, the workforce, particu-
larly in nursing, is declining”.
Research infrastructure emerged as another dimension,
in terms of fostering a supportive environment for clini-
cal and bench-top research. To support well-functioning
and productive research enterprises, more funding for
equipment and staff is also needed. In some countries,
universities do not offer the training required for breast
cancer research. Many countries cited acute shortage of
PhD-qualified researchers as hampering capacity for
breast cancer research.
Respondents identified a broad need for national sta-
tistics, a dimension covering a range of parallel issues,
including the need for benchmarking, national registries,
epidemiological statistics, and capacity for information
technology and data management. National statistics
require national investments in robust data collection
and management capacity to identify and explain poten-
tial differences in the occurrence of breast cancer
locally, in particular, whether there are disparities in the
incidence and etiology of breast cancer in different
populations.
Building capacity for public education to promote
widespread awareness of breast cancer was noted as an
important priority. Countries need to establish consis-
tent messaging that goes beyond at-risk populations to
generate widespread knowledge of breast cancer in the
general population. For example, one country had
already incorporated breast cancer awareness into public
media campaigns and school programs to demonstrate
“...how to do breast self-examination and to make this at
least a monthly routine“.
T h ep r o p e n s i t yt od i s c u s si s s u e so fbuilding capacity
was relatively consistent across the regions (Table 5),
with the exception of the propensity to discuss research
infrastructure (p = 0.01) and national statistics (p =
0.003). With regards to discussing research infrastruc-
ture, the propensity was highest in Latin America (59%)
and lowest in Asia (30%), with Middle East/North Africa
(31%) and Canada/Australia (41%) falling in between.
The need for national statistics was discussed most
Figure 1 Countries included in the analysis. Figure 1 identifies the countries included in the study. Countries included in the study were (with
number of respondents per country presented in parentheses): Asia: South Korea (20); China (19); Taiwan (16); India (13); Thailand (6); Malaysia
(5); Philippines (5); Indonesia (5); Singapore (4); Vietnam (1). Latin America: Mexico (19); Brazil (19); Argentina (6); Peru (1); Chile (1). Middle East/
North Africa: Turkey (20); Egypt (5); UAE (3); Lebanon (3); Pakistan (3); Saudi Arabia (2); Jordan (1); Syria (1); Oman (1); Morocco (1); Tunisia (1);
Algeria (1). Control group: Australia (17); Canada (22).
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Theme Dimension Concepts
Building
capacity
Science and
research
Capacity for basic and clinical science; funding for clinical research; trained nurses/staff for clinical research.
Skilled nurses Capacity to train nurses for patient care and patient education and to provide qualified nursing support.
Research
infrastructure
Capacity for clinical research; need for research laboratories; need for research equipment.
National statistics Capacity to investigate local incidence and characteristics of breast cancer; IT capacity to support national
registries and research.
Public education Capacity for national public education and awareness campaigns on breast cancer and screening.
Developing
evidence
Study of local
etiology
Evidence identifying differences between local patients and those in the UK/USA; younger women; more
aggressive tumor morphology.
Personalized
therapy
Evidence to promote personalized therapy; includes using genetic targets to tailor treatment.
Developing
guidelines
Research in local populations and other evidence to inform local guidelines and policies; national treatment
guidelines and coordination.
International
networks
Connecting to evidence internationally; keeping up to date; global research programs, networking and
education opportunities.
Local
communication
Communicating evidence across stakeholders; improved communications between/within institutions and
across institutions within areas or the country.
Removing
barriers
Out-of-pocket
costs
Barriers due to out-of-pocket expenses paid for by the patient.
Disparities in
access
Barriers for underserved and rural populations.
High cost to
payers
Barriers to reimbursing high-cost treatments.
Early detection Barriers to accessing earlier detection.
Reimbursement Barriers to accessing therapies that are not yet proven to be cost effective.
Promoting
advocacy
Patient
empowerment
Strategies to empower patients/patient groups and inform consumers.
Managing
survivorship
Support increased focus on survivors; long-term side-effects and quality of life.
Quality of life Support increased focus in research and practice on quality of life.
Metastatic
disease
Support for the management of metastatic disease.
Organized
advocacy
Support for leadership and staffing of advocacy groups; communication between advocacy groups.
Table 4 Dimensions of building capacity
Dimension Representative quote
Science and
research
“Research is our major issue. We are getting farther and farther behind the rest of the world.”
[Physician from Middle East/North Africa]
Skilled nurses “We depend upon employing nurses from other countries to fill our needs. This hampers our ability to advance breast cancer care of
our own people, by our own people.”
[Surgeon from Middle East/North Africa]
Research
infrastructure
“How can we do basic research when there will be no jobs for these PhDs upon completing years of study, or when for the same
investment of their time and talents, they will find more lucrative jobs as physicians.” [Researcher from Australia]
National statistics “Without a long term commitment to developing data at a national level, we cannot develop the appropriate guidelines and
policies appropriate to our own population.”
[Physician from Latin American]
Public education “Public education, especially on the importance of early detection, is key.”
[Policy maker from Asia]
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Canada/Australia (56%), at a rate higher than in Latin
America (37%) and much higher than in Asia (27%).
Theme 2: Developing evidence
The second theme that emerged from our discussions
with the key informants was centered on developing evi-
dence, including dimensions such as the study of local
etiology, developing suitable approaches to personalized
therapy, developing guidelines,f o s t e r i n ginternational
networks and promoting local communication to enable
sharing of and the ability to build upon collective
experience. Representative quotes relating to the dimen-
sions of developing evidence, are presented in Table 6
and are discussed in full below.
Study of local etiology focused on the need to collect
and analyze data in a way that identifies variations in
disease etiology, such as higher proportions of breast
cancer diagnosis among younger women, more aggres-
sive disease, and differences in tumor morphology of
breast cancer in the respondents’ home country.
Personalized therapy was generally expressed as a
need to focus on individual patient treatment, support
and other care, including utilization of targeted thera-
pies. Interestingly, there was significant regional varia-
tion in terms of the frequency with which personalized
therapy was discussed. In Latin America, for instance,
there was a great deal of general interest in persona-
lized therapy. In the Middle East/North Africa, interest
in personalized approaches was motivated by the rela-
tively high number of women who present with late
stage breast cancer.
Developing guidelines at the national level was a major
dimension of the developing evidence theme and is
related to both the need for national statistics and the
coordination of practitioners, researchers, advocates and
policymakers. Some respondents stressed that guidelines
were nonexistent, unclear or incomplete, or lacked
appropriate stakeholder representation during develop-
ment. Often guidelines were merely copied from inter-
national standards, without reference to local needs,
circumstances, or resources.
Table 5 Propensity to discuss each dimension by region
Asia
N=9 7
Latin Am
N=4 6
ME/NA
N=3 9
Aus/Can
N=3 9
p value
Building capacity (%)
Science and research 51.5 50.0 56.4 46.2 0.84
Skilled nurses 50.5 41.3 51.3 38.5 0.48
Research infrastructure 29.9
a 58.7
b 30.8
a, b 41.0
a, b 0.01
National statistics 26.8
a 37.0
a, b 51.3
a, b 56.4
b 0.003
Public education 42.3 47.8 46.2 33.3 0.56
Developing evidence (%)
Study of local etiology 23.7 37.0 28.2 33.3 0.38
Personalized therapy 36.1
a 82.6
b 20.5
a 48.7
a < 0.001
Developing guidelines 23.7
a 47.8
b 12.8
a 51.3
b < 0.001
International networks 52.6
a, b 63.0
b 30.8
a 66.7
b 0.01
Local communication 36.1
a 34.8
a 10.3
b 56.4
a < 0.001
Removing barriers (%)
Out-of-pocket costs 38.1
a, b 47.8
b 10.3
c 20.5
a, c < 0.001
Disparities in access 37.1
a, c 69.6
b 23.1
a 53.8
b, c < 0.001
High cost to payers 42.3 56.5 38.5 53.8 0.22
Early detection 45.4 50.0 46.2 41.0 0.88
Reimbursement 43.3
a, b 45.7
a, b 28.2
b 61.5
a 0.03
Promoting advocacy (%)
Patient empowerment 26.8
a 39.1
a, b 23.1
a, b 53.8
b 0.008
Managing survivorship 12.4
a 17.4
a 0.0
b 33.3
a 0.004
Quality of life 19.6 28.3 20.5 33.3 0.31
Metastatic disease 36.1 26.1 33.3 28.2 0.63
Organized advocacy 13.4
a, c 43.5
b 28.2
c 5.1
a < 0.001
Based on the Mariscuillo multiple comparisons procedure [21,22], common superscripts
a, b, c reflect paired comparisons that are not statistically different, while
pairs that are statistically different do not share the same superscript.
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ing evidence theme reflected the need for dynamic, con-
tinuous communication between local researchers/
clinicians and the international community. Such two-
way communications can be facilitated by global
research programs and international training programs.
As one respondent put it, there is a “...need for more
research with international exposure”. While countries
in South America had benefited from such networks,
respondents from the Middle East/North Africa were
significantly less likely to be engaged in collaborative
trials from outside of the region, and to send research
fellows to USA and EU.
Local communication related to the need for better
communication about research and practice within
multi-disciplinary teams, both within single organiza-
tions and across distinct organizations within the same
area or nation. Improved local communication, espe-
cially on research activities, can stimulate and reinforce
a culture of clinical and basic research. This need for
improved communication was mentioned even by those
countries with the highest level of commitment to
breast cancer research.
T h ep r o p e n s i t yt od i s c u s st h estudy of local etiology
was relatively common across the regions (see Table 5),
but significant variations existed in the propensity to
discuss the other dimensions: personalized therapy (p <
0.001), developing guidelines (p < 0.001), and communi-
cation (p < 0.001). Personalized therapy was discussed
among most respondents in Latin America (83%), and
much less in Asia (36%), Middle East/North Africa
(21%), and even Canada/Australia (49%). The propensity
to discuss developing guidelines was similar between
Latin America (48%) and Canada/Australia (51%), but
was discussed less often in Asia (24%) and far less often
i nt h eM i d d l eE a s t / N o r t hA f r i c a( 1 3 % ) .T h o s er e s p o n -
dents in the Middle East/North Africa (31%) discussed
international networks significantly less than those in
Latin America (63%) and Australia (67%), with respon-
dents in Asia (53%) falling in between. Finally, the focus
on local communication in Asia and Latin America was
almost identical (36% and 35%, respectively), and were
not statistically different than those of Australia/Canada
(56%). The results for Middle East/North Africa were
significantly different from all the other groups, with
communication discussed by only 10% of respondents.
Theme 3: Removing barriers
T h et h i r dt h e m ew a sremoving barriers to cancer con-
trol, including dimensions related to the high out-of-
pocket costs faced by many women with breast cancer,
addressing disparities in access,t h ehigh cost to payers
of breast cancer, the need for early detection of breast
cancer, and issues of cost-effectiveness that can act as a
barrier to the reimbursement of breast cancer treat-
ments. Selected quotes from respondents relating to the
dimension of removing barriers are presented in Table 7
and are discussed as follows.
The dimension of out-of-pocket costs mainly reflects bar-
riers to accessing care by patients who bear high costs of
care, not only directly with payments and co-payments but
also indirectly through travel costs or lost earnings, for
example. For the majority of the countries examined, there
is a lack of or insufficient insurance from either private or
public sectors. Where it is available, many procedures and
tests are not covered, or not covered adequately. The
inability of the average woman with breast cancer in these
countries to pay for diagnosis, prevention, or treatment
results in women presenting to hospitals with very late
stages of breast cancer, when prognosis is poorest.
The dimension of disparities in access highlights the
plight of poor, rural, and other underserved populations
in many countries who often have limited or no access
to screening, outpatient services, and breast cancer man-
agement. A lack of resources was often cited as the
main reason for these disparities, but issues such as
Table 6 Dimensions of developing evidence
Dimension Representative quote
Study of local
etiology
“Asian women get breast cancer earlier than US women. We need to know why.” [Hospital manager from Asia]
“We are seeing breast cancer in women 10 years earlier than Caucasians.” [Surgeon from Asia]
Personalized
therapy
“We need to individualize therapy; however, we have to follow a cook book approach or funds are cut.” [Physician from Canada]
Developing
guidelines
“Breast cancer in developing countries is not the same as in the West. We need non-Western clinical protocols to address the need
for screening among younger cohorts.”
[Hospital manager from Middle East/North Africa]
International
networks
“Currently, we have to wait every six months to meet in international conferences to exchange information with colleagues. I would
like to find the opportunity where I can discuss clinical issues more often with colleagues.”
[Academic from Asia]
Local
communication
“We should be continuously discussing and comparing notes within our own group as well as with other cancer centers, we should
be pooling and building on our collective local knowledge”
[Hospital Manager from Latin American]
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As one respondent put it, “many women in rural areas
have to travel and be away from home in order to access
care.” Many populations lack awareness of even basic
breast cancer services such as screening, highlighting a
need for “... underserved population[s] to be educated
regarding breast cancer”.
The high cost to payers dimension reflected difficulties
in reimbursing new high-cost treatments as well as cov-
ering basic care (e.g. screening and prevention) to a
growing population of patients. It highlighted insuffi-
cient reimbursement and funding by governments, pri-
vate insurance and other health plans. As both technical
capacity and patient needs grow, the “...biggest challenge
in the next few years is funding the high cost of breast
cancer drugs“.
Early detection was highlighted as a need for eliminat-
ing barriers to clinical and self-examination, including
screening among younger women, and the need for
more aggressive national policies and programs for early
detection and screening. Even though many of the coun-
tries that participated in our study have national aware-
ness programs, these do not reach a wide audience and
lead to disparities in early detection.
Barriers to access were further discussed in the con-
text of inability to demonstrate cost-effectiveness of new
technologies and therapies, which limits reimbursement
of costs therein. Respondents indicated that this is an
emerging problem, particularly for high-cost, targeted
therapies. As one clinician remarked, “The most signifi-
cant challenge is being able to demonstrate the cost-ben-
efit of breast cancer therapy in an objective way”.
Regions were relatively similar in the propensity to
discuss high costs to payers and early detection (see
Table 5). Significant variation was identified on the
dimensions of out-of-pocket costs (p < 0.001) and dispa-
rities in access (p < 0.001), and to a lesser extent for the
reimbursement dimension (p = 0.03). Patient out-of-
pocket costs were discussed most in Asia (38%) and
Latin America (48%), significantly more than in Middle
East/North Africa (10%). The propensity to discuss the
disparities in access dimension was greatest in Latin
America (70%), a figure that was similar to that in Aus-
tralia/Canada (54%) but significantly greater than that in
Asia (37%) and Middle East/North Africa (23%). The
dimension of reimbursement, covering issues of cost-
effectiveness, was most often discussed in Australia/
Canada (62%) where formal technology assessment pro-
cedures require cost-effectiveness before reimbursement,
but the rate of discussion was statistically similar for
Asia (43%) and Latin America (46%), although it was
significantly lower in Middle East/North Africa (28%).
Theme 4: Promoting advocacy
The fourth theme of our comprehensive framework for
national breast cancer control was promoting advocacy,
which covers issues such as promoting patient empower-
ment, managing survivorship,t h equality of life of
women with breast cancer, the need to focus on meta-
static disease,a n dt h en e e df o rorganized advocacy
efforts in breast cancer. Selected quotes for the dimen-
sions of promoting advocacy are presented in Table 8.
A prominent dimension of promoting advocacy was
patient empowerment. Respondents highlighted the need
for two-way communication between the healthcare sys-
tem and patients and patient groups, and for patients to
become increasingly involved in all aspects of decision-
making. Respondents stressed that such communication
needs to be tailored to reach groups with diverse back-
grounds. Respondents also highlighted a role for
improved patient involvement in underserved popula-
tions as a means by which to precipitate change.
T h en e e df o ra d v o c a c yt os u p p o r tt h ee m e r g i n gi s s u e
of managing survivorship was limited to certain regions
and respondents, due to the small number of advocates
and to the fact that many countries are still struggling
Table 7 Dimensions of removing barriers
Dimension Representative quote
Out-of-pocket
costs
“The government hospital will pay for a large portion of treatment, but women have to pay for the initial mammography and biopsy.
They have to have a positive diagnosis before the government will start paying. That is a huge deterrent.”
[Policy maker from Middle East/North Africa]
Disparities in
access
“Managing breast cancer among underserved populations is poor across the board. These populations are undereducated and the
government is not focusing on them.”
[Patient advocate from Australia]
High cost to
payers
“Our government will not pay for breast cancer for the majority of the population.” [Surgeon from Latin America]
Early detection “We need better strategies to encourage women of all ages to regularly practice self-detection. We estimate fewer than 5% of women
do this.” [Surgeon from Asia]
Reimbursement “The most significant challenge is being able to demonstrate the cost-benefit of breast cancer therapy in an objective way. There is a
particular issue around the affordability of drugs and associated pathology testing–particularly new drugs.”
[Hospital manager from Canada]
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Page 9 of 13with providing primary care or basic screening. Yet this
minority of respondents strongly emphasized that more
focus is needed on survivors in both research and prac-
tice. Specifically, more emphasis needs to be placed on
long-term side-effects, the ability of primary care provi-
ders to manage these survivors, and the quality of life
that survivors experience.
The quality of life of those with breast cancer also
emerged as an important dimension of the breast cancer
advocacy theme, in terms of both research and practice.
Notably, physician respondents in most countries
admitted to not having the time nor the training and
resources to counsel patients on what to expect during
or after surgery and/or chemotherapy. As one respon-
dent put it, “We don’t have time to discuss issues such as
quality of life during and after breast cancer treatment.”
Improved patient advocacy to highlight the plight of
patients with metastatic disease was also highlighted by
many respondents in each region, mainly in the context
of necessity of resources to provide palliative care.
Respondents indicated that this was of greater concern
when there were an increasing number of survivors or
when women delayed seeking medical care and pre-
sented for the first time at a later stage of disease.
Access to narcotics for pain control is a particularly
common issue in countries with limited resources.
Another concern expressed was the often prohibitive
cost versus benefits of treatment options in metastatic
disease.
Given the general lack of organized advocacy in many
of the regions studied, respondents indicated the need
for national strategies to improve organized advocacy
efforts. While advocacy normally starts at a ‘grass-roots’
level, respondents stressed the importance of advocacy
at the national level, where they could achieve signifi-
cant impact. More specifically, respondents recognized
that advocacy is needed to represent consumers and
patients in ways that medical thought leaders and policy
makers cannot. One respondent lamented the ‘Catch-22’
situation arising from a lack of advocacy, stating that
the “...government doesn’t want advocacy as breast can-
cer is not its priority, but without national advocacy,
who will represent the women?”
For the theme of promoting advocacy, the propensity
to discuss the quality-of-life and metastatic disease
dimensions were statistically similar across the four
regions (see Table 5). Differences were identified for the
dimensions of patient empowerment (p = 0.008), mana-
ging survivorship (p = 0.004) and organized advocacy (p
< 0.001). The propensity to discuss patient empower-
ment was statistically similar across Asia (27%), Latin
America (39%) and Middle East/North Africa (23%),
while it was most often discussed in Australia/Canada
(54%). The dimension of managing survivorship was sel-
dom discussed in the emerging regions (0-17%), but was
discussed by a third of respondents in Australia/Canada.
Finally, the need for organized advocacy efforts was dis-
cussed most in Latin America (44%), less in Middle
East/North Africa (28%) and Asia (13%) and rarely Aus-
tralia/Canada (5%) where breast cancer advocacy groups
and networks already exist at the federal level.
Discussion
While most countries have developed clinical guidelines
for the prevention and treatment of breast cancer, few
have developed comprehensive breast cancer control
plans. The themes and strategies identified in this study
provide countries with a template for developing
national breast cancer control plans or, potentially, a
mechanism for the assessment of existing control strate-
gies. Figure 2 presents our taxonomy for comprehensive
breast cancer control implementation, which can be
contrasted to that of the WHO [10]. We find that such
a framework must build capacity, take into account
developing evidence, remove barriers, and promote
patient advocacy. The taxonomy outlining the dimen-
sions of these four themes offers a useful template that
can foster both local and global action. As such, this
study is an important step towards developing an evi-
dence-based approach to assessing preparedness for
Table 8 Dimensions of promoting advocacy
Dimension Representative quote
Patient
empowerment
“We are challenged by women who are younger and better educated. They want to know everything and be involved with all
decisions [about their breast cancer].” [Policy maker from Australia]
Managing
survivorship
“We need more nurses and trained staff to take on the challenges related to the growing number of breast cancer survivors and the
increase of side effects including the long-term effects of worrying and on the family“ [Hospital manager from Latin America]
Quality of life “Quality of life is important because breast cancer patients can live for a long time and their emotional well being is important”.
[Patient advocate from Canada]
“We use quality-of-life protocols derived from western countries, however there are cultural differences that need to be incorporated.”
[Physician from Asia]
Metastatic disease “Women present for the first time at a late stage of disease - often metastatic“ [Physician from Middle East/North Africa]
Organized
advocacy
“Our government is very concerned about national breast cancer advocacy - if it gains power, then the government not only will
have to support it, but it will have to also pay attention to other cancer groups.” [Patient advocate from Asia]
Bridges et al. BMC Health Services Research 2011, 11:227
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Page 10 of 13implementing comprehensive breast cancer control stra-
tegies [7,9].
Our results have several commonalities with the
WHO guidelines for national cancer programs that span
six dimensions: prevention, early detection, diagnosis/
treatment, pain relief/palliative care, cancer control
research and surveillance [10]. This said, our conceptua-
lization has several unique areas (for example, persona-
lized therapy, reimbursement, managing survivorship
and organized advocacy) not present in the WHO
model. Likewise, as a comprehensive approach, our tax-
onomy does demarcate between stages of disease pro-
gression (a key feature of the WHO model), rather than
treating breast cancer control as a single entity. Further,
we draw no distinctions between the types of strategies
that should be used in countries with low, middle, and
high levels of resources. Our findings indicate that those
developing and implementing a comprehensive breast
cancer control strategy should have a single vision in
mind, irrespective of country size or level of develop-
ment. While it is certain that some countries lack the
resources to implement such a plan, focus on just a lim-
ited number of factors may lead to imbalances (for
example, screening is not useful if treatments are not
available/affordable and there is not capacity to care for
patients). This finding contrasts with existing calls for
cancer control strategies that are conditioned on the
level of resources available [25].
Our call for a more comprehensive approach to can-
cer control is not unique. In a recent review on the
development of cancer control in developing countries,
Hanna and Kangolle [26] call for a model that spans
prevention, early detection, diagnosis/treatment, and
palliation. Their model focuses around structure,
Comprehensive
Framework for
National Breast
Cancer Control
Strategies
Building capacity
Science and research
Skilled nurses
Research infrastructure
National statistics
Public education
Removing barriers
Out-of-pocket costs
Disparities in access
High cost to payers
Early detection
Reimbursement
Promoting advocacy
Patient empowerment
Managing survivorship
Quality of life
Metastatic disease
Organized advocacy
Developing evidence
Study of local etiology
Personalized therapy
Developing guidelines
International networks
Local communication
Figure 2 The comprehensive framework for national breast cancer control strategies. Figure 2 presents the comprehensive framework for
national breast cancer control strategies.
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with ours, including capacity for research, improved
national data, and an improved role of economic evalua-
tion (a key element in addressing the high cost to
payers). They too call for more local communication
and international collaboration.
A full discussion of the necessary implementation
strategies needed for comprehensive breast cancer con-
trol is beyond the scope of this paper and detailed stra-
tegies are provided elsewhere [10]. Furthermore, the
development of a comprehensive approach can draw
upon a host of lessons learned from international
experience [27].
Just as cancer care is complex and requires coordina-
tion [28], so does a national cancer control program. As
s e ei nF i g u r e2 ,o u rc o m p r e h e n s i v ef r a m e w o r kf o r
national breast cancer control requires activities in sev-
eral different areas (building capacity, developing evi-
dence, removing barriers, and promoting advocacy). The
simultaneous implementation of such a framework
would require dedicated resources for management and
stakeholder engagement, and a great deal of political
will.
The adoption of a national breast cancer control pro-
gram in Australia was facilitated by the creation of a
National Breast Cancer Center in 1995 that utilized a
continuous quality improvement approach to enhancing
all aspects of the breast cancer experience [29]. Through
the creation/consolidation of data and engagement with
stakeholders, the National Breast Cancer Center has
identified priority areas of need and developed resources
to support interventions. Some of its activities are simi-
lar to areas identified in our model, including public
awareness, capacity for science and research, developing
guidelines and promoting the use of specialty breast
cancer nurses [29].
In countries with low levels of resources, national can-
cer control can be achieved without the creation of new
institutions, but through better communication and
coordination of existing centers (or what is referred to
as local communication in our model). Such a model
has been used to coordinate a general cancer control
program in Uganda that has attracted international col-
laborations (also a factor in our model) [30].
It is important to note several limitations in the study.
First, the study was conducted among thought leaders
from a limited set of countries, and findings may have
differed if other countries had been included. Second,
our findings may have been influenced by our own
frame of reference and preconceptions, although several
standard qualitative research techniques were used to
mitigate this. Third, clinicians dominated our sample
d u em a i n l yt op r e d o m i n a n c eo fm e d i c a li n f l u e n c ei n
breast cancer decision-making, and also due to the
significant lack of policy and national advocacy leaders
specifically in breast cancer in these lower resourced
countries. Finally, we also recognize that the views of
our respondents may change over time.
While our framework offers a template for countries
around the world to assess their preparedness to address
the challenges of breast cancer, additional research is
needed to validate our taxonomy. Such validation would
require a more robust consideration of the elements of
the framework, including an assessment of the feasibility
and effectiveness of the individual strategies. Upon vali-
dation, we envision that our framework can be used to
make detailed comparisons across countries and to
develop comprehensive evidence-based policy strategies
for breast cancer management. This would require the
translation of the elements of our model (Figure 2) into
indicators that could be assessed as part of a national
breast cancer control checklist.
Conclusions
Our model may promote more comprehensive and sen-
sitive measurement of the challenges presented, so that
the themes and dimensions identified in lessening breast
cancer-related morbidity and mortality in these regions
may be adequately assessed and developed. Moreover,
the identification of needs, challenges and trends may
help clinicians, researchers, policy leaders and advocates
plan effective interventions that focus on previously
overlooked areas specific to breast cancer control. While
our framework offers a template to assess preparedness
to address the challenges of breast cancer, additional
research is needed to validate the taxonomy. Upon vali-
dation, we envision that our framework can be used to
make detailed cross-country comparisons and to develop
evidence-based policy strategies for breast cancer
control.
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